Drug Profile
Voyager V1 - Vyriad
Alternative Names: VSV-IFNβ-NIS; VSV-IFNβ-NIS - VyriadLatest Information Update: 07 Jul 2023
Price :
$50
*
At a glance
- Originator Vyriad
- Developer Mayo Clinic; National Cancer Institute (USA); Regeneron Pharmaceuticals; Vyriad
- Class Antineoplastics; Cancer vaccines; Gene therapies; Immunotherapies; Oncolytic viruses
- Mechanism of Action Cell death stimulants; Immunologic cytotoxicity
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Phase II Endometrial cancer; Liver cancer; Multiple myeloma; Non-small cell lung cancer
- Phase I/II Colorectal cancer; Neuroendocrine tumours; Solid tumours
- Phase I Acute myeloid leukaemia; T-cell lymphoma
Most Recent Events
- 07 Jul 2023 Pharmacokinetics data from a phase I/II trial in Solid tumours and Colorectal cancer presented at the 59th Annual Meeting of the American Society of Clinical Oncology (ASCO-2023)
- 02 Jun 2023 Updated efficacy and adverse event data from a phase I trial in Acute myeloid leukaemia presented at the 59th Annual Meeting of the American Society of Clinical Oncology (ASCO-2023)
- 23 May 2022 to be QCed; KDM updated